The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
Shengnan Ren(Second Affiliated Hospital of Nanjing Medical University), Zhao-xia Wang(Second Affiliated Hospital of Nanjing Medical University)
Cited by 10
Related Papers
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer
|European Journal of Medicinal Chemistry|2021|20